NFKB1 and renal fibrosis: Additionally, it markedly reduces the release of inflammatory cytokines and hinders the TLR4/NF-κB and MAPK signaling pathways, indicating Salidroside’s potential as a promising therapeutic approach for renal fibrosis [95].